NCT01316185View on ClinicalTrials.gov

Proof-of-concept Study Evaluating the Safety and Efficacy of EBP921 in Delta Hepatitis (HDV)

PHASE1TerminatedINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

January 31, 2011

Primary Completion Date

April 30, 2013

Study Completion Date

April 30, 2013

Conditions
Hepatitis D
Interventions
DRUG

EBP921

Patients randomized to receive low or high dose. All dosing of EBP921 should be taken with food.

Trial Locations (2)

48202

Henry Ford Hospital, Detroit

Unknown

San Francisco

Sponsors
All Listed Sponsors
lead

Eiger BioPharmaceuticals

INDUSTRY

NCT01316185 - Proof-of-concept Study Evaluating the Safety and Efficacy of EBP921 in Delta Hepatitis (HDV) | Biotech Hunter | Biotech Hunter